Literature DB >> 730072

Vasoactive intestinal peptide in man: pharmacokinetics, metabolic and circulatory effects.

S Domschke, W Domschke, S R Bloom, P Mitznegg, S J Mitchell, G Lux, U Strunz.   

Abstract

Graded doses of 0.6, 1.3, and 3.3 pmol/kg/min of vasoactive intestinal peptide (VIP) were intravenously infused over 30 minute periods in four healthy volunteers and plasma VIP levels were measured by radioimmunoassay. Even with the smallest dose of VIP, plasma concentrations rose markedly above normal values. Infusion of higher VIP doses resulted in mean plateau levels of circulating VIP which were in the range of VIP values found in the Verner-Morrison syndrome. After cessation of the VIP infusions, plasma VIP levels fell strikingly by first order kinetics with an average disappearance half-time of one minute. The apparent metabolic clearance rate was about 9 ml/kg/min and the apparent volume of distribution for VIP was approximately 14 ml/kg. During infusion of the highest VIP dose, previously shown to induce one-fifth maximum pancreatic juice secretion, plasma concentrations of glucose, free fatty acids, and calcium were slightly but significantly raised, the pulse rate and the amplitude of blood pressure were increased, and cutaneous flushing occurred. The spectrum of effects accords well with some abnormalities seen in the Verner-Morrison syndrome. The present data, however, do not support a role for VIP as a circulating hormone, at least under physiological conditions.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 730072      PMCID: PMC1412244          DOI: 10.1136/gut.19.11.1049

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  19 in total

1.  Microdetermination of long-chain fatty acids in plasma and tissues.

Authors:  V P DOLE; H MEINERTZ
Journal:  J Biol Chem       Date:  1960-09       Impact factor: 5.157

2.  Vasoactive intestinal peptide: a secretin-like partial agonist for pancreatic secretion in man.

Authors:  S Domschke; W Domschke; W Rösch; S J Konturek; W Sprügel; P Mitznegg; E Wünsch; L Demling
Journal:  Gastroenterology       Date:  1977-09       Impact factor: 22.682

Review 3.  The newer gut hormones. Cellular sources, physiology, pathology, and clinical aspects.

Authors:  A G Pearse; J M Polak; S R Bloom
Journal:  Gastroenterology       Date:  1977-04       Impact factor: 22.682

4.  Lipolytic action of a newly isolated vasoactive intestinal polypeptide.

Authors:  E K Frandsen; A J Moody
Journal:  Horm Metab Res       Date:  1973-05       Impact factor: 2.936

5.  Polypeptide with broad biological activity: isolation from small intestine.

Authors:  S I Said; V Mutt
Journal:  Science       Date:  1970-09-18       Impact factor: 47.728

Review 6.  Pharmacology of hypothalamic regulatory peptides.

Authors:  W Vale; C Rivier; M Brown; J Leppaluoto; N Ling; M Monahan; J Rivier
Journal:  Clin Endocrinol (Oxf)       Date:  1976       Impact factor: 3.478

7.  Measurement of fasting and postprandial plasma VIP in man.

Authors:  S J Mitchell; S R Bloom
Journal:  Gut       Date:  1978-11       Impact factor: 23.059

8.  Effect of vasoactive intestinal polypeptide infused intrapancreatically on glucagon and insulin secretion.

Authors:  A Kaneto; T Kaneko; H Kajinuma; K Kosaka
Journal:  Metabolism       Date:  1977-07       Impact factor: 8.694

9.  Radioimmunoassay of vasoactive intestinal polypeptide (VIP) in plasma.

Authors:  J Fahrenkrug; O V Schaffalitzky de Muckadell
Journal:  J Lab Clin Med       Date:  1977-06

10.  Release of VIP by calcium stimulation.

Authors:  A M Ebeid; P Murray; P B Soeters; J E Fischer
Journal:  Am J Surg       Date:  1977-01       Impact factor: 2.565

View more
  25 in total

1.  Glycogenolytic effect of vasoactive intestinal peptide in the rat in vivo.

Authors:  V Sánchez; R Goberna; J R Calvo
Journal:  Experientia       Date:  1991-06-15

2.  Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal Peptide significantly better than sterically stabilized micelles.

Authors:  Sandra Reichstetter; Gerardo M Castillo; Israel Rubinstein; Akiko Nishimoto-Ashfield; Manshun Lai; Cynthia C Jones; Aryamitra A Banerjee; Aryamitra Banjeree; Alex Lyubimov; Duane C Bloedow; Alexei Bogdanov; Elijah M Bolotin
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

3.  Radioimmunoassay study of hepatic clearance and disappearance half-time of somatostatin and vasoactive intestinal peptide in dogs.

Authors:  J A Chayvialle; P L Rayford; J C Thompson
Journal:  Gut       Date:  1981-09       Impact factor: 23.059

4.  The pharmacokinetics of VIP in dog and pig.

Authors:  S J Mitchell; I M Modlin; A A D'Sa Barros; S R Bloom
Journal:  Experientia       Date:  1982-09-15

5.  Stapled Vasoactive Intestinal Peptide (VIP) Derivatives Improve VPAC2 Agonism and Glucose-Dependent Insulin Secretion.

Authors:  Fabrizio Giordanetto; Jefferson D Revell; Laurent Knerr; Marie Hostettler; Amalia Paunovic; Claire Priest; Annika Janefeldt; Adrian Gill
Journal:  ACS Med Chem Lett       Date:  2013-10-16       Impact factor: 4.345

6.  Bile salt inhibition of motility in the isolated perfused rabbit terminal ileum.

Authors:  D N Armstrong; H K Krenz; I M Modlin; G H Ballantyne
Journal:  Gut       Date:  1993-04       Impact factor: 23.059

7.  Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis.

Authors:  Varun Sethi; Israel Rubinstein; Antonina Kuzmis; Helen Kastrissios; James Artwohl; Hayat Onyuksel
Journal:  Mol Pharm       Date:  2013-01-23       Impact factor: 4.939

8.  Effects of vasoactive intestinal polypeptide on renal function in man.

Authors:  J Calam; R Dimaline; W S Peart; J Singh; R J Unwin
Journal:  J Physiol       Date:  1983-12       Impact factor: 5.182

9.  Hepatic metabolism of vasoactive intestinal polypeptide during liver transplantation in the pig.

Authors:  C Palnaes Hansen; S Boesby; P Kirkegaard
Journal:  J Endocrinol Invest       Date:  1991-06       Impact factor: 4.256

10.  HCl-stimulated duodenal HCO3- secretion in conscious rat. Interactions among VIP, nicotinic receptor mechanisms, and prostaglandins.

Authors:  B Smedfors; E Theodorsson; C Johansson
Journal:  Dig Dis Sci       Date:  1994-10       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.